Serum S100A8 as an early diagnostic biomarker in patients with community-acquired pneumonia

Abstract

IntroductionLimited studies have suggested that calprotectin may take part in the pathophysiology of community-acquired pneumonia (CAP). Nevertheless, there is no clinical study analysing the role of S100A8 in CAP patients. The objective of this study was to analyse the association of serum S100A8 with the severity of CAP and determine the cut-off values of S100A8 for predictive power based on a cross-sectional study.Material and methodsA total of 200 CAP patients and 100 normal subjects were recruited. Demographic data, clinical information, and serum were collected on admission. S100A8 and inflammatory cytokines were detected using ELISA and RT-PCR. All statistical analyses were performed with SPSS 19.0.ResultsSerum S100A8 was increased in CAP patients on admission. Serum S100A8 was gradually increased in parallel with CAP severity scores. Serum S100A8 was positively correlated with CAP severity scores, blood routine parameters, and inflammatory cytokines. Furthermore, univariate and multivariate logistical regression revealed that there were positive associations between serum S100A8 with CRB-65, PSI, and CURXO. Moreover, the predictive capacity of serum S100A8 was determined by ROC curve analysis. The area under the curves of S100A8 for CAP and CAP severity were 0.855 and 0.893, respectively. Mechanistic analysis found that S100A8 knockdown alleviated streptococcus pneumoniae-evoked inflammatory cytokines in A549 cells.ConclusionsSerum S100A8 on admission was positively associated with the severity of CAP. S100A8 knockdown alleviates streptococcus pneumoniae-evoked inflammatory cytokines in A549 cells, indicating that S100A8 may exert a significant effect on the pathophysiology of CAP and could be an early serum diagnostic biomarker for CAP.

Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study

“…All selected 239 CAP patients in this research must meet certain diagnostic standard: In accord with the clinical manifestations of pneumonia and consistent with chest CT scans, mainly including (1) chest radiograph suggesting either a new patchy infiltrate, leaf or segment consolidation, ground glass opacity or interstitial change; (2) at least one of the following signs: the presence of cough, sputum production and dyspnoea; core body temperature higher than 38.0 °C; auscultatory findings of abnormal breath sounds and rales; or the counts of white blood cell more than 10 × 10 9 L or less than 4 × 10 9 L; (3) occurred in the community, rather than in a hospital [ 22 ]. The inclusion criteria were as follows: pneumonia was occurred in the community or within a definite incubation period after hospitalization; these candidates were not admitted to the hospital for the last three months; not pregnant; no other pulmonary diseases, such as pulmonary malignant tumor, pulmonary tuberculosis or immunodeficiency [ 23 , 24 ]; no antibiotic treatment or intervention before hospitalization. Peripheral blood samples were collected and anticoagulated with EDTA within 24 h after hospitalization.…”

Calprotectin: An Ignored Biomarker of Neutrophilia in Pediatric Respiratory Diseases

“…Fang et al investigated the correlations between the serum S100A8 heterodimer and the severity of community-acquired pneumonia (CAP) and inflammatory cytokines in adults [ 79 ]. Another objective was to establish S100A8 cutoff values for predictive power in CAP patients.…”

Serum Level of 4-Hydroxynonenal in Community-Acquired Pneumonia: A Potential Biomarker for Severity and Prognosis

“…However, the role of 4-HNE was unclear in patients with CAP. Some studies from our team have demonstrated that inflammation and oxidative stress exert important roles in the pathophysiology of CAP (29)(30)(31)(32). Hence, it is reasonable to infer that 4-HNE may be involved in the process of CAP.…”